BCMA-targeted immunotherapy for multiple myeloma

Volume: 13, Issue: 1, Pages: 125 - 125
Published: Sep 17, 2020
Abstract
B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a...
Paper Details
Title
BCMA-targeted immunotherapy for multiple myeloma
Published Date
Sep 17, 2020
Volume
13
Issue
1
Pages
125 - 125
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.